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Background: We systematically reviewed the evidence for the interaction of microsatellite instability status (MSI)
and treatment with 5FU in colorectal cancer to determine how well MSI status predicts health outcomes in patients
undergoing 5FU-based chemotherapy.
Methods: We conducted a search of four electronic databases through June 2013. We considered studies that
included both colorectal cancer patients treated with 5FU-based chemotherapy and untreated patients with survival
outcomes presented by MSI status.
Results: We identified 16 studies for qualitative analysis (9,212 patients) with 14 studies eligible for meta-analysis.
The microsatellite stable (MSS) group showed an effect of 5FU treatment on disease-free survival (HR of 0.62
[95% CI: 0.54, 0.71]) and overall survival (HR of 0.65 [95% CI: 0.54, 0.79]), indicating that MSS patients who received
5FU treatment had longer survival than MSS patients who were untreated. The effect of 5FU treatment was not
statistically significant for microsatellite high (MSI-H) patients for disease-free survival (HR of 0.84 [95% CI: 0.53, 1.32])
or overall survival (HR 0.66 [95% CI: 0.43, 1.03]). However, the summarized point estimates of the effects of 5FU
treatment for the MSS and MSI-H groups were not different at a statistically significant level.
Conclusions: Our analyses indicate that treatment with 5FU-based chemotherapy improves disease-free and overall
survival in CRC patients, but that there is no difference in the effect of treatment based on MSI status. Therefore,
the use of MSI status to guide treatment decisions about the use of 5FU treatment for CRC has no significant
benefits for patients.
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Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer in the United States; about 1 in 20
Americans will develop CRC in their lifetime. Although
the death rate from CRC has been dropping, it remains
the third leading cause of cancer-related deaths [1].
About 15% of CRC tumors develop via a pathway char-
acterized by defective function of the DNA mismatch re-
pair (MMR) system. MMR deficiency most commonly
occurs through epigenetic inactivation of the MLH1
gene in sporadic CRCs, but can also occur through
inherited mutations in any one of four genes (i.e.,* Correspondence: Katrina.ab.goddard@kpchr.org
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unless otherwise stated.MLH1, MSH2, MSH6, and PMS2). Tumors with MMR
deficiency exhibit a high frequency of microsatellite in-
stability (MSI-H) because these regions of the genome
are particularly unstable and susceptible to errors that
do not get corrected because of the defective MMR sys-
tem [2]. For determining MSI status, the National Can-
cer Institute (NCI) recommends a microsatellite panel
(NCI panel) consisting of two mononucleotide repeats
(BAT26 and A4725) and three dinucleotide repeats
(D5S346, D2S123, and D17S250). Using the NCI panel,
MSI-H tumors are defined as having instability in two or
more markers, and tumors with low or stable microsat-
ellite instability have instability in one or no markers [3].
Tumor MMR status is also determined by immunohisto-
chemical (IHC) analysis of the protein products of genesl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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MSH6, and PMS2 [4].
In advanced stage CRC patients, the fluoropyrimidine
5-fluorouracil (5FU) has been the most widely used che-
motherapeutic agent since the late 1950s [5]. 5FU, alone
or in combination with other drugs, is recommended for
first-line treatment in Stage III, Stage IV, and high risk
Stage II CRC [6]. Recently, there has been some sugges-
tion that MSI-H status, from either hereditary or ac-
quired causes, could potentially guide treatment
decisions for this very commonly used chemotherapeutic
agent [7]. The expected effect of using MSI status to guide
treatment decisions is to withhold treatment with 5FU for
individuals who are unlikely to respond or to use alterna-
tive chemotherapies. Clinical practice guidelines provide
conflicting recommendations about the use of MSI status
to guide 5FU treatment decisions. Three major cancer
guideline groups have stated that use of MSI for predicting
response to therapy is not recommended [8-10]. Alterna-
tively, updated guidelines for 2013 from the National
Comprehensive Cancer Network recommend MSI testing
for all patients with Stage II disease because MSI positive
patients may have a good prognosis and do not benefit
from 5FU therapy [6].
There is substantial data on the relationship between
MSI status and prognosis in CRC patients. A meta-
analysis with 7,642 cases demonstrated that patients
with MSI-H tumors have a significantly better prognosis
than those with MSS tumors [7]. This prognostic benefit
of MSI-H status can confound the relationship between
MSI and treatment effects, especially when only treated
patients are considered. Figure 1 demonstrates that
MSI-H patients appear to have better survival, even in
the absence of a treatment benefit; their improved sur-
vival comes from the prognostic benefit of their MSI sta-













Adapted from Barratt 2002.25
Figure 1 MSI status is a prognostic and predictive marker.
Adapted from Barratt 2002 [26].We systematically reviewed the evidence for the inter-
action of microsatellite instability status (MSI) and treat-
ment with 5FU in colorectal cancer to determine how




We considered studies that included both CRC patients
treated with 5FU-based chemotherapy and untreated pa-
tients with survival outcomes presented by MSI status.
We accepted either MSI or IHC testing to indicate MSI
status. While any treatment containing 5FU therapy was
included, we required that >90% of patients received
5FU in the treatment group for inclusion of the study.
Eligible study designs included randomized controlled or
controlled clinical trials and prospective or retrospective
cohort studies. We excluded studies that did not report
disease free survival (DFS) or overall survival (OS) out-
come separately for patients based on MSI and treat-
ment status (or where data could not be calculated).
Identification of studies
Systematic literature searches were performed in the fol-
lowing databases through June 27, 2013: MEDLINE,
PubMed, Cochrane Database of Systematic Reviews, and
Cochrane Central Register of Controlled Trials. The
search strategy was built to comprehensively capture the
literature related to MSI and chemotherapeutic agents in
the context of CRC treatment. Search details are pro-
vided in the supplementary materials (see Additional file
1: Search Strategy). The database searching was supple-
mented by the review of reference lists from existing re-
views, hand searching selected scientific conferences
from 2010-2013, and a search of ongoing and recently
completed studies on clinicaltrials.gov.
Identified abstracts were independently reviewed by
two investigators against inclusion criteria specified a
priori. Full-text articles of abstracts meeting inclusion
criteria were dual-reviewed against the inclusion criteria.
Disagreements were resolved through consensus or the
input of a third reviewer.
We reviewed studies for the independence of their
study populations. In the case where multiple studies
were identified with population overlap, we included the
study that presented the needed data with the largest
number of participants.
Quality assessment and data abstraction
At least two investigators independently assessed the qual-
ity of each included study using questions adapted from
the QUADAS-2 (Table 1) [11]. Overall quality codes were
determined by discussion and consensus between the two
reviewers. Quality categories of good, fair+, fair-, and poor
Table 1 Article quality rating
Quality rating questions Quality categories
• Were the test(s) clearly described (number of loci tested, MMR genes, etc?)
AND did the Index test(s) meet NIH standards?
• Good: Studies with a low risk of bias and minimal
concerns of applicability
• Was the spectrum of patients/tumors representative of the patients/tumors
who will receive the test in practice?
• Fair+: Studies with some risk of bias or concerns regarding
applicability; testing does meet NIH standards
• Was the patient (sample) selection process from the source population
(retrospective studies) clearly described? If prospective, were patient
selection criteria clearly described?
• Fair -: Studies with some risk of bias or concerns regarding
applicability; testing does not meet NIH standards
• In a retrospective study, were selected samples representative
(50% of original sample number; not statistically different on key
characteristics e.g. stage distribution) of the original complete sample set?
• Poor: Studies with a significant risk of bias or greater
concerns regarding applicability
• Were patient withdrawals (prospective) or sample losses (retrospective)
from the source population explained?
• Were un-interpretable, indeterminate, or intermediate test results
reported? (Includes samples with insufficient DNA)
• Was follow-up sufficiently long? (minimum 3 years)
• If prospective, was treatment assignment blinded to MSI status?
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about applicability of each study. Despite the limitations of
categorizing studies in this manner [12], these categories
were used for ease of grouping. Studies that were consid-
ered poor quality were excluded from the analysis.
Data related to study design, population characteris-
tics, chemotherapy use, MSI testing method and com-
pleteness, and relevant outcomes were abstracted from
included studies into evidence tables with dual data
checking by a second reviewer. Disagreements were re-
solved through consensus or input of a third reviewer.
Studies were included in the analysis regardless of stage
at diagnosis for the patients. We classified the studies as
‘advanced stage’ or ‘mixed stages.’Advanced stage refers to
study populations in which all patients had metastatic
CRC, and distant metastases. Mixed stages refers to studies
with a combination of patients from Stage I to Stage IV at
diagnosis.
Testing was classified by ‘completeness.’ MSI testing was
considered complete if at least the 5 marker NCI panel was
tested according to NCI standards. Testing using fewer
markers was considered incomplete. For IHC, testing was
considered complete if the presence of proteins for all four
genes (MLH1, MSH2, MSH6, and PMS2) was evaluated,
and incomplete if one to three proteins were tested.
Regimens that included 5FU alone or with leucovorin
only were classified as single agent treatment. Regimens
that included 5FU in combination with other therapies,
such as (but not limited to) FOLFOX, FOLFIRI, or
CAPOX were classified as multi-drug treatment.
Studies were classified depending on the type of can-
cer for the patient, including colon only, rectal only, and
colon/rectal combined.
When possible, we recorded outcomes data from
multivariate analyses that adjusted for other potentiallyconfounding variables. If only univariate analysis was re-
ported, we recorded these results instead, but also
retained an indicator of which analysis is reported.
Statistical analysis
The hazard ratio (HR) and 95% confidence interval was
abstracted from each article where possible. In cases
where the HR was not reported, the value was estimated
using the methods described by Tierney et al. [13] HR
analysis involved transforming data to ensure that for all
studies a HR lower than 1 referred to improved survival
in the group receiving 5FU chemotherapy compared to
the group receiving no treatment. In general, data asso-
ciated with the longest follow-up was retained; however,
in instances where patient groups within the same study
had variable lengths of follow up, estimates were made
for all groups at the shortest time point to allow all
groups equivalent time to accrue events.
We conducted random-effects meta-analyses to estimate
the pooled effect size of disease-free survival (DFS) and
overall survival (OS). We used the metan procedure in
Stata 11.2® [14] for all meta-analyses, which implements
the DerSimonion & Laird method [15]. Analyses were
stratified by patient MSI status (MSI-H versus MSS). To
examine the statistical significance of the pooled estimates
in different strata, we calculated the difference in the log
of the pooled effects and their standard error, and from
those statistics calculated a z-score and related p-values.
Because the DerSimonian & Laird methods can underesti-
mate statistical heterogeneity when heterogeneity is high
or few studies are being pooled, we ran sensitivity analyses
using the Profile Likelihood estimation method [16]. Re-
sults were almost identical between the two methods, so
DerSimonian & Laird results are presented in the text and
figures.
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heterogeneity. We applied the Cochrane Collaboration’s
rules of thumb for interpreting I2: less than 40 percent
likely represents unimportant heterogeneity, 30 to 60
percent represents moderate heterogeneity, 50 to 90 per-
cent represents substantial heterogeneity; above 75 per-
cent indicates considerable heterogeneity among the
studies [17]. We did not conduct any analyses to assess
the presence of publication bias or selective outcome
reporting within our included studies.
DFS is defined in various ways throughout the CRC lit-
erature. Measures of DFS vary in their beginning time
point (diagnosis, randomization, and enrollment) and in-
cluded endpoints (recurrence, progression, and death). In
addition to studies of DFS, other studies reported related
surrogate endpoints including recurrence-free survival or
time to recurrence. Similar variation exists in the measure-
ment of overall survival (OS) in oncology literature. Some
studies of survival include only cancer-specific deaths while
others include all-cause deaths. It is unclear whether this
lack of consistency between trials may alter the findings of
a systematic review [18]. In order to examine the impact of
these heterogeneous endpoints, multiple sensitivity ana-
lyses were conducted from least to most restrictive defin-
ition for DFS and OS. The most restrictive were based on
definitions published by the FDA in 2007 for guiding clin-
ical trial endpoints [19]. We also performed a subset ana-
lysis to assess the study findings in stage II only.
Results
Eligible studies
The literature search identified 815 articles for evalu-
ation against the eligibility criteria. We excluded 624 ar-
ticles based on review of the abstract, and retrieved and
evaluated 191 full text articles. After review, 16 studies
were included for qualitative analysis and 14 studies
were eligible for meta-analysis (see Excluded Studies list
in Additional file 1: Search Strategy). The Literature
Flow Diagram is presented in Figure 2.
We excluded 46 studies that only reported on subjects
treated with 5FU (with no comparison to an untreated
population) that would have otherwise been included.
For DFS, there were 6 articles that were retained for the
meta-analysis of HR [20-25]. For OS there were 14 arti-
cles that were retained for the meta-analysis of HR
[20-33]. Two studies [34,35] are included in qualitative
discussion but they did not provide the necessary data to
be included in the meta-analysis.
All papers were rated as fair quality with the exception
of one paper [33] that was rated as good quality. Two
papers were excluded from this review based on poor
quality [36,37]. Lukish et al. [36] was considered poor
quality because the MSI testing was not performed ac-
cording to the NCI standards [3], all patients were lessthan 40 years old so the population was not representa-
tive of a general population, and the study had a small
sample size. Bertagnolli et al. [37] was considered poor
quality because the treated and untreated groups were
decided by stage and therefore the difference in out-
comes is likely highly confounded in terms of prognosis.
The fair quality papers were divided into two groups
based on whether the MSI testing met NCI standards
[20,21,23,25,28-30,34,35] or not [22,24,26,27,31,32].
Microsatellite instability (MSI)
Overall, nine studies were classified as having complete
testing for MSI status [20,21,23,25,28,29,33-35]. Ten
studies used MSI testing only [20,23,25-29,33-35], 4
studies used IHC testing only [24,30-32], and 2 studies
used both MSI and IHC testing to determine MSI status
[21,22]. For the purposes of this analysis, subjects were
classified as either MSI high (MSI-H) or MSI low or
stable (MSS). The mean percentage of MSI-H subjects
was 15% for the included studies, which is comparable
to the expected percentage of MSI-H based on popula-
tion estimates [38].
Study characteristics
Characteristics of the eligible studies are provided in
Table 2. There were a total of 9,312 subjects included
across all studies. All of the studies included for the final
analysis used treatment regimens that included 5FU as a
single agent. One study also included a separate analysis
of a small subset of patients (n = 16) that received 5FU,
leucovorin, and oxaliplatin (FOLFOX); however, this sam-
ple size is too small to draw a meaningful conclusion [32].
Studies were included in the analysis regardless of pa-
tient stage at diagnosis. Although in most cases the pro-
portion of patients at each stage was reported, results
were not stratified by stage, so results are reported for
all stages combined. An analysis focused on stage II
cases is presented after the results that included all
stages combined. Most studies included both rectal and
colon cancer.
MSI status and effect of 5FU treatment based on disease
free survival (DFS)
Forest plots of the effect of 5FU treatment on DFS by
MSI status are shown using HRs (Figure 3). For the MSS
group, there was an effect of 5FU treatment on DFS with
summary HR of 0.62 (95% CI: 0.54, 0.71), indicating that
patients who received 5FU treatment had longer DFS
than patients who did not receive this treatment. We did
not detect evidence of heterogeneity across studies for
the MSS group for the HR analysis (I2 = 7.5%, p = 0.37).
In contrast, the effect of 5FU treatment on DFS was not
statistically significant for MSI-H patients with a pooled
HR of 0.84 (95% CI: 0.53, 1.32). We did not detect
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group (I2 = 13.9%, p = 0.33). The sample size for the MSI-
H group is smaller than the sample size for the MSS group
(651 vs. 4434), and the confidence interval for each study
is wider for the MSI-H group compared with the MSS
group.
Comparing the summarized point estimates of the effect
of 5FU treatment for the MSS group to the MSI-H group,
there is not a statistically significant difference (p = 0.11).
Thus, we did not find evidence that MSI status affects the
likelihood of DFS with 5FU treatment, however data were
limited.
One study [35] reported on DFS but could not be in-
cluded in the quantitative synthesis because it was notFigure 2 Literature flow diagram.possible to estimate the HR using the data available in the
publication. In this study, the median DFS was very similar
for treated and untreated patients with MSI-H status
(34 months versus 36 months, respectively), and for pa-
tients with MSS status (24 months versus 25 months,
respectively).
We conducted sensitivity analyses to determine whether
the results of the analysis are affected by the definition of
the DFS outcome. The primary analysis we presented
above is the broadest and most inclusive, and incorporated
all studies that presented a HR of anything described by
the authors as DFS or regression free survival (RFS), which
could include substantially different definitions. In sensi-
tivity analyses, we restricted the analysis only to studies
Table 2 Study characteristics
Study sample characteristics 5FU
Treatment
regimen
MSI assessment Included in HR meta-analysis
Study N Tumor Stage % stage II % stage IV MSI test version MSI test completeness MSI-H (%) DFS OS
Hong 2012 [12] 947 Colorectal Mixed 40% 16.9% NR MSI Complete 9% X2 X2
Hutchins 2011 [11] 1913 Colorectal Mixed 89% 0% Single IHC Partial 11% X1 X1
Jover 2009 [21] 496 Colorectal Mixed 59%3 0% Single MSI+IHC Complete 12% X2 X2
Kim 2007 [25] 542 Colon Mixed NR 0% Single MSI Complete 18% X1 X1
Sargent 2010 [22] 1027 Colon Mixed 52% 0% Single MSI+IHC Partial 16% X2 X2
Storojeva 2005 [23] 160 Colorectal Mixed NR NR Single MSI Complete 13% X2 X2
Barratt 2002 [26] 368 Colon Mixed 61%3 NR Single MSI Partial 24% X
Benatti 2005 [28] 1263 Colorectal Mixed 58%3 14.6% Single MSI Complete 20% X
Carethers 2004 [29] 204 Colorectal Mixed 52% 0% Single MSI Complete 18% X1
Elsaleh 2001 [27] 732 Colorectal Mixed 0% 0% Single MSI Partial 9% X
Lanza 2006 [30] 325 Colorectal Mixed 0% 0% Single IHC Partial 13% X1
Liang 2002 [33] 244 Colorectal Advanced 0% 100% Single MSI Complete 21% X1
Ohrling 2010 [31] 718 Colorectal Mixed 50% 0% Single IHC Partial 20% X1
Wangefjord 2013 [32] 112 Colorectal Mixed 0% 0% Single IHC Partial 15% X1
Colombino 2002 [35] 91 Rectal Mixed 42% NR Single MSI Complete 19%
Dietmaier 2006 [34] 170 Colon Mixed 0% 0% Single MSI Complete 14%
Ribic 570 Colon Mixed 55% 0% Single MSI Partial 17%
Total 9312 15%
(5FU = 5 fluorouracil; DFS = disease free survival; OS = overall survival; HR = hazard ratio; NR = not reported; MSI = microsatellite instability; IHC = immunohistochemistry; X = study was included in the analysis).
1Hazard ratio had to be estimated from study (see Methods).
2Multivariate hazard ratio used in analysis.
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definition for DFS [21,22]. When only these two studies
are included, there is a statistically significant difference in
the effect of 5FU treatment on DFS based on MSI status
(p = 0.008). The pooled HRs were quite different, however
data was limited to only two studies with only 225 persons
with MSI-H (MSI-H:pooled HR = 1.38 (95% CI: 0.77 –
2.49), MSS: HR = 0.60 (95% CI: 0.42 – 0.85), data not
shown).
MSI status and effect of 5FU treatment based on overall
survival (OS)
Forest plots of the effectiveness of 5FU treatment on OS
by MSI status are shown using the HR (Figure 4). 5FU
treatment was effective in increasing OS in the MSS
group with a summary HR of 0.65 (95% CI: 0.54, 0.79),
indicating that patients who received 5FU treatment had
longer OS than patients who did not receive this treat-
ment. There was evidence of substantial heterogeneity
across studies for the MSS group (I2 = 79%, p < 0.001).
The largest estimate of the effect of treatment was seen
in the study with the shortest followup [20]. In general,
there appeared to be a trend of decreasing benefit as the
years of observation increased.
The effect of 5FU treatment on OS was very similar for
MSI-H patients with a pooled HR of 0.66 (95% CI: 0.43,
1.03), although the difference between those treated andFigure 3 Forest plot of hazard ratios (HRs) for the effect of 5FU treatm
ratios less than 1.0 indicate longer DFS for patients who receive 5FU treatm
difference in the HR for the MSI-H versus MSS groups was not statistically snot treated with 5FU was not statistically significant in this
group. There was evidence of substantial heterogeneity
across studies for the MSI-H group (I2 = 66%, p < 0.001).
This heterogeneity across studies may be driven by lower
estimates of the effect of treatment for two studies [27,33],
and in general there were relatively small sample sizes
with fewer than 100 observations per study in most cases.
The confidence intervals around the point estimates for
each study are wider for the MSI-H group compared with
the MSS group, reflecting the smaller number of patients
with MSI-H status (e.g., overall N = 1293 vs. 6685 for
MSI-H and MSS, respectively).
Not surprisingly, the pooled estimates the effect of 5FU
treatment were not statistically different between the two
groups (p = 0.45). Thus, it is unlikely the 5FU treatment
has a differential effect on OS based on MSI status, how-
ever uncertainty remains due to the relatively few events in
the MSI-H group and the wide variability in HRs in that
group. We note that effect sizes were smaller for MSI-H
than MSS patients in all but two of the studies with
follow-up of 8 years or less, though differences were not
statistically significant. Given the small number of events,
these results are consistent with either a reduced likeli-
hood of improved OS for MSI-H patients or no difference
between groups.
Two studies [34,35] reported on OS that could not be
included in the quantitative synthesis because it was notent on disease-free survival (DFS) by MSI status. By convention,
ent compared with untreated patients. The test of significance for the
ignificant (p = 0.111).
Figure 4 Forest plot of hazard ratios (HRs) for the effect of 5FU treatment on overall survival (OS) by MSI status. By convention, ratios
less than 1.0 indicate longer OS for patients who receive 5FU treatment compared with untreated patients. The test of significance for the
difference in HR for MSI-H versus MSS groups was not statistically significant (p = 0.45). Benatti et al. [28] was included in the figure and point
estimate, but this study was removed for calculation of p-values, since it contributed data only to the MSI-H group.
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the publications. In one study, the median OS was very
similar for treated and untreated patients with MSI-H
status (both 37 months), and for patients with MSS sta-
tus (26 months versus 28 months, respectively). In the
second study, patients who received treatment with 5FU
had fewer events compared with untreated patients for
MSI-H (OR = 0.40; 95% CI: 0.07 – 2.34) and MSS (OR =
0.45; 95% CI: 0.23 – 0.90) patients, with a median
follow-up of 44.5 months.
As with DFS, we conducted sensitivity analyses to deter-
mine whether the results of the analysis were affected by
definition of the OS outcome. In sensitivity analyses, we
used increasingly restrictive definitions: 1) only studies
that use all-cause mortality [20-23,25,26,31,33] 2) only
studies that use cancer-specific survival [27,28,32] and 3)
only studies that use the FDA definition of OS
[21,22,24,26,33]. These analyses did not change the find-
ings, except that in the analysis of studies that use cancer-
specific survival the pooled HR estimate for the MSS
group was no longer statistically significantly different
from 1.0, presumably because of the small sample sizewith only two studies contributing to the analysis [data
not shown].
MSI status and effect of 5FU treatment in stage II cases
only
We assessed the relationship between MSI status and
treatment with 5FU in stage II cases only, because the
NCCN guidelines recommend MSI testing for treatment
decisions only in this group [6]. There was very limited
data available to address this question, since most pub-
lished studies conducted a joint analysis of mixed stages,
and did not provide stratified data by stage. We found
three studies that provide data on stage II cases only with
a total of 1319 subjects [22,28,39], and one study where
the study population included a very high percentage
(91%) of stage II cases with a total of 1708 subjects
(Table 2) [24]. Because the data did not use consistent
measures across studies, we did not perform a meta-
analysis. Instead, we provide a qualitative description of
the results.
Ribic et al. [39] reported no difference in OS in MSS
patients (HR = 0.67; 95% CI 0.39 – 1.15), or in MSI-H
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of follow-up. Sargent et al. [22] reported similar findings
for DFS, with no difference in DFS for MSS patients
(HR = 0.84; 95% CI 0.57 – 1.24; p = 0.38) or for MSI-H
patients (HR = 2.30; 95% CI 0.84 – 6.24; p = 0.09) de-
pending on treatment status. For the OS outcome, they
reported that the conclusions were similar (data not
shown) except that for MSI-H patients the 5FU treated
group had decreased OS compared with surgery alone
(HR = 2.95; 95% CI 1.02 – 8.54; p = 0.04). Benatti et al.
[28] reported no difference in OS for MSS patients (log
rank = 2; p = 0.151) or for MSI-H patients (log rank =
0.97; p = 0.323) depending on 5FU treatment status with
5 years of follow-up. Hutchins et al. [24] reported a differ-
ence in DFS for MSS patients (HR 0.59; 95% CI 0.45 –
0.77), but not for MSI-H patients (HR = 0.81; 95% CI 0.29
– 2.33) with 10 years of follow-up [Figure 2]. For OS, there
was not difference in either group based on MSI status
[Figure 3]. Consistent with the findings for all stages com-
bined, these studies suggest a potential trend towards larger
beneficial effects of treatment in MSS patients compared
with MSI-H patients, although the differences are not sta-
tistically significant.
In order to incorporate data from as many studies as
possible, we also considered all of the studies ranked by
percentage of stage II patients. We did not observe a
pattern suggesting a relationship between the percentage
of stage II patients and response to 5FU by MSI status
(see Additional file 2: Figure S1 & Additional file 3:
Figures S2).
Discussion
We assessed MSI status as a predictive marker for health
outcomes in patients undergoing treatment with 5FU-
based chemotherapy. The results of this meta-analysis
showed that treatment with 5FU-based chemotherapy
improved DFS and overall survival in MSS patients and
there was a statistically non-significant trend towards
better survival in MSI-H patients with 5FU treatment,
and no clear difference in the effect of treatment based
on MSI status.
Our results expand upon the results of a previous
meta-analysis of the same topic by Guastadisegni et al.
[40], which included a total sample size of 3121, com-
pared with 9312 subjects in the present analysis. All of
the studies reported in the previous analysis are included
in our analysis, with the exception of one study [39] that
had an overlapping population with a larger and more
recent study that was included in our analysis [22]. The
previous analysis also differed from ours in the statistical
procedures used to compute the summary statistic. We
used methods to estimate the HR [13], which takes into
account the number and timing of events, and censor-
ing. Odds ratios (ORs) take into account only thenumber of events, and can produce biased estimates for
time-to-event outcomes. The authors of the previous
analysis on this topic concluded that whereas they could
establish MSI status as a favorable prognostic marker
based on DFS (summary OR = 0.58, 95% CI 0.47 – 0.72)
and OS (summary OR = 0.6; 95% CI 0.53 – 0.69) for
CRC patients, they had inconclusive results for MSI sta-
tus as a predictive marker of response to treatment with
5FU chemotherapy. Similar to our analysis, they deter-
mined that there was a significant beneficial effect of
5FU chemotherapy in patients with MSS tumors (OR =
0.52; 95% CI 0.4 – 0.6). However, the sample size for pa-
tients with MSI-H tumors in their analysis was small
(n = 396). The point estimate for the effect of 5FU treat-
ment in MSI-H patients was similar to what we found
(OR = 0.69; 95% CI 0.3 – 1.5) for OS, and there was sig-
nificant heterogeneity across studies (p = 0.03), so no
clear conclusion could be reached. Our analysis included
a larger population of 1293 MSI-H patients; however,
statistically significant heterogeneity was still identified
in the overall survival analysis.
Des Guetz et al. [41] also reported a meta-analysis on
this topic that included seven studies with 3690 patients
combined, six of which were reported by Guastadisegni
et al. [40] All patients included in these studies are
Stage II or Stage III CRC cases. Given this overlap, not
surprisingly they found a beneficial effect of chemother-
apy among MSS patients, but no benefit of 5FU chemo-
therapy among MSI-H patients for Regression-Free
Survival (HR = 0.96; 95% CI 0.62 – 1.49) or OS (HR =
0.70, 95% CI 0.44 – 1.09). In contrast to the conclusions
of Guastadisegni et al. [40], these authors concluded
that MSI-H status is a predictive factor of non-response
to 5FU chemotherapy based on a meta-analysis for the
interaction between MSI status and treatment effect,
suggesting a lesser benefit for MSI-H patients compared
with MSS patients ((HR = 0.77, 95% CI 0.68 – 0.87).
A previous study addressed this question and reached
seemingly different conclusions. Des Guetz et al. [42] con-
ducted a meta-analysis restricted only to patients with
metastatic CRC who received treatment with 5FU chemo-
therapy. The results were reported in terms of the re-
sponse rate ratio using the RECIST criteria [43]. The
authors found that among patients treated with 5FU
chemotherapy, the response rate ratio was 0.82 (95% CI
0.65 – 1.03), where ratios less than 1.0 indicate that the re-
sponse rate to chemotherapy was better among MSI-H
patients compared with MSS patients. However, the au-
thors concluded that MSI status does not predict the ef-
fect of 5FU chemotherapy. When we repeated this
analysis with existing studies [33,44-54], however, we had
a statistically significant finding. For studies in which
patients were treated with 5FU as a single agent, the
summary RR is 0.52 (95% CI 0.40 – 0.68), indicating that
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apy than MSS patients (see Additional file 4: Figure S3).
This apparent discrepancy can be understood by consider-
ing Figure 1, which shows the expected impact of MSI
status as both a prognostic and predictive factor. By evalu-
ating only patients who received 5FU treatment, we
cannot untangle the effects of prognosis and treatment.
Interestingly, in this analysis we observed a substantially
different effect for studies in which patients were treated
with 5FU as a single agent versus studies in which patients
received 5FU as part of a combination therapy. Unfortu-
nately, none of the studies in our primary meta-analysis
used combination therapy, so we were unable to confirm
whether this effect remained using different outcomes
(DFS, OS) or subjects with different stages of CRC.
The data that we report do not support the recom-
mendation for determination of MSI status in stage II
CRC patients. One guideline recommends determin-
ation of MSI status for all patients with stage II disease
because stage II MSI-H patients may have good progno-
sis and do not benefit from 5FU treatment [6]. This
guideline only cites the results of one study [22], which
was also reported by us, showing a statistically signifi-
cant decrease in OS in the treatment group compared
with surgery alone in MSI-H stage II patients (HR =
2.95; 95% CI 1.02 – 8.54; p = 0.04). This was the only
study with a statistically significant finding; the others
showed no difference for stage II patients in MSI-H pa-
tients. Further, this study had the most extreme HR in
favor of no 5FU treatment for MSI-H patients among
studies that reported on stage II patients (Additional file
2: Figure S1 and Additional file 3: Figure S2).
There were several limitations to our meta-analysis.
First, not all studies reported hazard ratios or counts of
events, which were the primary data necessary to include
the studies in the meta-analysis. In some cases, we were
able estimate the HR value using the methods described
by Tierney et al. [13]. We conducted a sensitivity ana-
lysis by excluding studies in which the data were esti-
mated, and the overall conclusions remained the same
(data not shown). Related to this issue, a second limita-
tion of our approach is that when we estimated data
using the Kaplan-Meier curves, we selected the longest
possible follow-up available to determine the estimated
number of events. This approach could lead to potential
bias towards the null hypothesis of no difference, be-
cause Figures 3 and 4 show a possible trend with the
most significant HRs being the ones with the shortest
follow-up time.
None of the studies reported in our primary meta-
analysis used contemporary treatment regimens that in-
clude 5FU in combination therapies, such as FOLFOX
or FOLFIRI. This is a strength of the available data, since
it is then possible to explore the ability of MSI status topredict 5FU treatment response in isolation, and without
contamination of the effects of other treatments given
simultaneously. However, it is not clear that these find-
ings represent the effect of MSI status on response to
5FU in combination therapy.
We did not consider whether molecular subtypes of
MSI-H patients experience differential response to 5FU
chemotherapy. Greater heterogeneity of MSI-H tumors
is now recognized [55] with various epigenetic and gen-
etic alterations that may alter the prognostic and pre-
dictive implications for patients. For instance, recently,
large deletions in HSP110 T17 have been associated with
improved survival in patients treated with 5FU-based
chemotherapy [56,57]. Future analyses may need to ac-
count for this heterogeneity.
Finally, despite the increase in sample size for this
analysis compared with previously reported meta-
analyses on this topic, the number of MSI-H patients
available for analysis remains limited, with substantially
larger confidence intervals and lower statistical power
compared with the findings for the MSS group. This
limitation is coupled with an evidence base that relies
primarily on retrospective study designs that have a
greater potential for selection bias, and substantial (al-
though not significant) heterogeneity of effect sizes re-
ported in studies. One ongoing prospective study was
identified in our search for additional clinical trials and
meeting abstracts: The Eastern Cooperative Oncology
Group (ECOG) E5202 Trial (ClinicalTrials.gov Identi-
fier: NCT00217737) will assign treatment arms for stage
II colorectal cancer patients based on MSI status in
conjunction with 18q LOH. Those patients who are
considered high risk (based on MSS and 18q LOH) will
be randomized to FOLFOX6 with or without bevacizu-
mab. Patients considered low risk due to retention of
18q alleles or MSI-H status will receive observation
alone. While no publications were identified for this
study, the clinical trial record indicates that primary
data collection is completed.
Conclusions
We conclude that the results of this meta-analysis do
not support the use of MSI status for the direct benefit
of the patient in guiding decisions about the use of 5FU
treatment for CRC. Testing for MSI status among CRC
patients is becoming increasingly common [58], given
efforts to implement recommendations for universal
screening of newly diagnosed CRC patients to identify
cases of Lynch Syndrome [59]. Whereas substantial
benefit of MSI testing has been demonstrated in terms
of impact on relatives [60] and impact on prognosis [7],
there remains limited use of this testing in guiding
treatment decisions for patients already diagnosed with
CRC.
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Additional file 1: Search strategy used to identify relevant studies
in Medline.
Additional file 2: Figure S1. Forest plot of hazard ratios (HRs) for the
effect of 5FU treatment on disease-free survival (DFS) by MSI status
ranked by percentage of stage II patients. By convention, ratios less than
1.0 indicate longer DFS for patients who receive 5FU treatment compared
with untreated patients. The test of significance for the difference in the HR
for the MSI-H versus MSS groups was not statistically significant (p = 0.111).
Additional file 3: Figure S2. Forest plot of hazard ratios (HRs) for the
effect of 5FU treatment on overall survival (OS) by MSI status ranked by
percentage of stage II patients. By convention, ratios less than 1.0 indicate
longer OS for patients who receive 5FU treatment compared with untreated
patients. The test of significance for the difference in HR for MSI-H versus
MSS groups was not statistically significant (p = 0.45). Benatti et al. [28] was
included in the figure and point estimate, but this study was removed for
calculation of p-values, since it contributed data only to the MSI-H group.
Additional file 4: Figure S3. Forest plot of response rate ratio (RR) for
the effect of MSI status on response to treatment among patients treated
with 5FU therapy. By convention, ratios less than 1.0 indicate a better
response to treatment among patients with MSI-L/S status.
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